VCP and myocardial infarction: A new substance (KUS121), which inhibits the ATPase activity of VCP/p97, has been shown to exert protective effects in in vivo myocardial infarction models, and in in vitro cardiomyocyte hypoxia models [57], which is contradictory to a study involving VCP/p97 K524A transgenic mice [10].